Iterum Therapeutics plc (ITRM)
NASDAQ$1.395+0.05 (3.73%)
Market Cap
$46.34M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
659 of 924
Rank in Industry
373 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ITRM Insider Trading Activity
ITRM Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Iterum Therapeutics plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Activity of Iterum Therapeutics plc
Over the last 12 months, insiders at Iterum Therapeutics plc have bought $0 and sold $0 worth of Iterum Therapeutics plc stock.
On average, over the past 5 years, insiders at Iterum Therapeutics plc have bought $74,998 and sold $17.07M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $35,000 was made by Dunne Michael W. (director) on 2023‑12‑22.
List of Insider Buy and Sell Transactions, Iterum Therapeutics plc
| 2023-12-22 | Dunne Michael W. | director | 25,000 0.1716% | $1.40 | $35,000 | +2.14% | ||
| 2023-12-18 | Dunne Michael W. | director | 10,000 0.0794% | $1.84 | $18,442 | -17.82% | ||
| 2023-11-22 | Dunne Michael W. | director | 20,000 0.1507% | $2.03 | $40,690 | -30.92% | ||
| 2023-11-20 | Fishman Corey N. | Chief Executive Officer | 10,000 0.0872% | $1.59 | $15,863 | +3.62% | ||
| 2022-12-02 | Sale | Puttagunta Sailaja | Chief Medical Officer | 3,365 0.0261% | $1.32 | $4,442 | -23.02% | |
| 2022-03-14 | Sale | Matthews Judith M. | Chief Financial Officer | 63,340 0.029% | $0.31 | $19,635 | -62.16% | |
| 2022-03-11 | Sale | Matthews Judith M. | Chief Financial Officer | 47,132 0.0261% | $0.38 | $17,910 | -61.10% | |
| 2021-02-12 | Sale | DENNER ALEXANDER J | 10 percent owner | 10.62M 8.7758% | $2.27 | $24.11M | -69.11% | |
| 2021-02-11 | Sale | DENNER ALEXANDER J | 10 percent owner | 10M 9.0673% | $2.59 | $25.9M | -70.30% | |
| 2021-01-26 | Sale | Fishman Corey N. | President & CEO | 170,890 0.077% | $0.86 | $147,820 | -49.75% | |
| 2021-01-26 | Sale | Dunne Michael W. | director | 33,143 0.0299% | $1.73 | $57,337 | -49.75% | |
| 2021-01-26 | Sale | Matthews Judith M. | Chief Financial Officer | 33,868 0.0305% | $1.73 | $58,592 | -49.75% | |
| 2020-10-27 | Dunne Michael W. | Chief Scientific Officer | 123,080 0.3428% | $0.33 | $40,001 | +124.28% | ||
| 2020-09-30 | Sale | Matthews Judith M. | Chief Financial Officer | 112,260 0.3651% | $0.82 | $92,053 | +5.71% | |
| 2020-06-02 | Sale | Sofinnova Venture Partners IX, L.P. | 10 percent owner | 800,000 2.5418% | $0.80 | $642,960 | -32.10% | |
| 2020-06-01 | Sale | Sofinnova Venture Partners IX, L.P. | 10 percent owner | 200,000 0.6371% | $0.85 | $169,120 | -35.29% | |
| 2018-11-30 | Kelly David George | director | 20,000 0.1148% | $3.14 | $62,887 | +2.19% | ||
| 2018-10-30 | Chin Mark | director | 116,000 1.3004% | $6.10 | $707,600 | +3.21% | ||
| 2018-09-04 | Dunne Michael W. | Chief Scientific Officer | 1,000 0.0038% | $5.00 | $5,000 | -30.64% | ||
| 2018-08-27 | Dunne Michael W. | Chief Scientific Officer | 1,000 0.0071% | $10.00 | $10,000 | -34.86% |
Total: 35
Insider Historical Profitability
16.26%
| Ahrens Brenton Karl | director | 1733170 5.0119% | $2.32M | 1 | 0 | |
| CANAAN X L.P. | 1733170 5.0119% | $2.32M | 1 | 0 | ||
| HEALY JAMES | 1726514 4.9926% | $2.31M | 1 | 0 | ||
| Sofinnova Venture Partners IX, L.P. | 10 percent owner | 1226514 3.5467% | $1.64M | 1 | 2 | |
| Heron Patrick J | director | 1197161 3.4619% | $1.6M | 1 | 0 |
Historical Insider Profitability vs. Competitors
$1,695,621 | 55 | 17.90% | $43.58M | |
$15,956,086 | 53 | 5.33% | $44.72M | |
$18,274,594 | 22 | -26.07% | $47.82M | |
$1,087,418 | 21 | 1.95% | $43.46M | |
$160,539,875 | 21 | -6.57% | $47.61M |
ITRM Institutional Investors: Active Positions
| Increased Positions | 14 | +66.67% | 627,492 | +30.75% |
| Decreased Positions | 6 | -28.57% | 1M | -70.45% |
| New Positions | 11 | New | 592,669 | New |
| Sold Out Positions | 5 | Sold Out | 1M | Sold Out |
| Total Postitions | 29 | +38.1% | 1M | -39.71% |
ITRM Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Renaissance Technologies Llc | $612.00 | 1.25% | 438,816 | +438,816 | New | 2024-12-31 |
| New Leaf Venture Partners, L.L.C. | $481.00 | 0.99% | 345,020 | 0 | 0% | 2024-12-31 |
| Apollon Financial, Llc | $349.00 | 0.72% | 250,250 | +25,500 | +11.35% | 2024-12-31 |
| Creative Financial Designs Inc /Adv | $84.00 | 0.17% | 59,900 | +59,900 | New | 2024-12-31 |
| Two Sigma Investments, Lp | $35.00 | 0.07% | 25,245 | +25,245 | New | 2024-12-31 |
| Citadel Advisors Llc | $30.00 | 0.06% | 21,207 | +21,207 | New | 2024-12-31 |
| Sanctuary Advisors, Llc | $28.00 | 0.06% | 20,000 | +20,000 | New | 2024-12-31 |
| Lee Financial Co | $22.00 | 0.05% | 16,000 | +16,000 | New | 2024-12-31 |
| Alpine Global Management, Llc | $21.00 | 0.04% | 15,000 | -49,833 | -76.86% | 2024-12-31 |
| Geode Capital Management, Llc | $17.00 | 0.04% | 12,370 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.